Richard R. Furman, MD | Authors

Articles

42-Month Follow-Up Data of Acalabrutinib Monotherapy in R/R CLL

December 10, 2019

Richard R. Furman, MD, professor of medicine, Morton Coleman, MD Distinguished Professor of Medicine, director, Chronic Lymphocytic Leukemia Research Center, Weill Cornell Medicine, and attending physician, NewYork-Presbyterian Hospital, discusses the 42-month follow-up data of acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia.

Using Idelalisib Instead of Chemotherapy to Treat CLL

May 08, 2014

Richard R. Furman, MD, a member of the Lymphoma/Myeloma Service in the Division of Hematology/Oncology at the New York Weill Cornell Medical Center, discusses the ability to avoid the administration of chemotherapy when using novel agents, such as idelalisib, to treat patients with chronic lymphocytic leukemia.

Efficacy and Safety of Idelalisib and Rituximab for Previously Treated CLL

January 08, 2014

Richard R. Furman, MD, Richard A. Stratton Assistant Professor in Hematology and Oncology, Weill Cornell Medical College, gives an overview of the efficacy and safety of idelalisib and rituximab for previously treated CLL.